Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA
Molecules · 2024
DOI: 10.3390/molecules29112658 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2024. Verfasst von Jamie Leckie und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Cell-Penetrating Peptides, Muscular Atrophy, Spinal, Oligonucleotides, Antisense. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Muscular Dystrophy Canada, Friends of Garrett Cumming Research Fund, HM Toupin Neurological Science Research Fund.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a severe neuromuscular disorder that is caused by mutations in the survival motor neuron 1 (SMN1) gene, hindering the production of functional survival motor neuron (SMN) proteins. Antisense oligonucleotides (ASOs), a versatile DNA-like drug, are adept at binding to target RNA to prevent translation or promote alternative splicing. Nusinersen is an FDA-approved ASO for the treatment of SMA. It effectively promotes alternative splicing in pre-mRNA transcribed from the SMN2 gene, an analog of the SMN1 gene, to produce a greater amount of full-length SMN protein, to compensate for the loss of functional protein translated from SMN1. Despite its efficacy in ameliorating SMA symptoms, the cellular uptake of these ASOs is suboptimal, and their inability to penetrate the CNS necessitates invasive lumbar punctures. Cell-penetrating peptides (CPPs), which can be conjugated to ASOs, represent a promising approach to improve the efficiency of these treatments for SMA and have the potential to transverse the blood–brain barrier to circumvent the need for intrusive intrathecal injections and their associated adverse effects. This review provides a comprehensive analysis of ASO therapies, their application for the treatment of SMA, and the encouraging potential of CPPs as delivery systems to improve ASO uptake and overall efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
- The Friends of Garrett Cumming Research & Muscular Dystrophy Canada HM Toupin Neurological Sciences Research, Edmonton, AB T6G 2H7, Canada.
ORCID-Profile: Toshifumi Yokota
Förderung
- Muscular Dystrophy Canada
- Friends of Garrett Cumming Research Fund
- HM Toupin Neurological Science Research Fund
- Canadian Institute of Health Research (CIHR)
- Alberta Innovates: Health Solutions (AIHS)
- Jesse’s Journey
- Women and Children’s Health Research Institute (WCHRI)
- Heart and Stroke Foundation Canada, and the US Department of Defense
Zitieren
APA
Leckie, J., & Yokota, T. (2024). Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA. Molecules. https://doi.org/10.3390/molecules29112658
Vancouver
Leckie J, Yokota T. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA. Molecules. 2024. doi:10.3390/molecules29112658
BibTeX
@article{Leckie2024,
author = {Leckie, Jamie and Yokota, Toshifumi},
title = {Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29112658}
}
EUVIMED